US006040292A

United States Patent [19]

Sommer

[11] **Patent Number: 6,040,292**

[45] **Date of Patent: Mar. 21, 2000**

[54] **METHODS FOR TREATING DIABETES**

[75] Inventor: **Andreas Sommer**, Danville, Calif.

[73] Assignee: **Celtrix Pharmaceuticals, Inc.**, San Jose, Calif.

[21] Appl. No.: **09/326,189**

[22] Filed: **Jun. 4, 1999**

[51] **Int. Cl.**[7] **A61K 38/00**

[52] **U.S. Cl.** **514/12**

[58] **Field of Search** 514/12

[56] **References Cited**

U.S. PATENT DOCUMENTS

4,988,675	1/1991	Froesch et al.	514/4
5,407,913	4/1995	Sommer et al. .	
5,466,670	11/1995	Dunger et al.	514/12
5,527,776	6/1996	Carlino et al. .	
5,674,845	10/1997	MacCuish	514/12
5,681,818	10/1997	Spencer et al. .	
5,686,408	11/1997	Moses et al.	514/3
5,723,441	9/1998	Higley et al. .	

FOREIGN PATENT DOCUMENTS

WO 95/03817	2/1995	WIPO .
WO 95/04076	2/1995	WIPO .
WO 95/13823	5/1995	WIPO .
WO 96/02565	2/1996	WIPO .

OTHER PUBLICATIONS

Blum et al., 1991, "Plasma IGFBP–3 Levels as Clinical Indicators "in *Modern Concepts in Insulin–Like Growth Factors*, E.M. Spencer, ed., Elsevier, New York, pp. 381–393.

Clark et al., 1993, "Insulin–like Growth Factor–I Stimulation of Lymphopoiesus "*J. Clin. Invest.*92:540–548.

Clemmons et al., 1994, "Uses of Human Insulin–like Growth Factor–1 in Clinical Conditions "*J. Clin. Endocrinol. Metabol.*79(1):4–6.

Delany et al., 1994, "Cellular and Clinical Perspectives on Skeletal Insulin–like Growth Factor I "*J. Cell. Biochem.* 55:328–333.

Guler et aL., 1987, "Short–term Metabolic Effects of Recombinant Human Insulin–like Growth Factor I in Healthy Adults", *New England J. Med.* 317(3):137–140.

Lewis et al., 1993, "Insulin–like Growth Factor I: Potential for Treatment of Motor Neuronal Disorders "*Exp. Neurol.* 124:73–88.

Lieberman et al., 1992, "Effects of Recombinant Human Insulin–like Growth Factor–I (rhIGF–I) on Total and Free IGF–I Concentrations, IGF–Binding Proteins, and Glycemic Response in Humans", *J. Clin. Endocrinol. Metab.* 75(1):30–36.

Radulescu, Razvan T., 1994, *Trends Biochem Sci.* 19(7):278.

Sommer et al., 1991, "Molecular Genetics and Actions of Recombinant Insulin–Like Growth Factor Binding Protein–3", in *Modem Concepts of Insulin–Like Growth Factors*, E.M. Spencer, ed., Elsevier, New York, pp. 715–728.

Steenfos, Henrik H., 1994, "Growth Factors and Wound Healing "*Scand. J. Plast. Reconstr. Hand Surg.* 28:95–105.

Zapf et al., 1994, "Intravenously Injected Insulin–like Growth Factor (IGF) I/IGF Binding Protein–3 Complex Exerts Insulin–like Effects in Hypophysectomized, but Not in Normal Rats", *J. Clin. Invest.* 95:179–186.

Primary Examiner—Raymond Henley, III
Attorney, Agent, or Firm—Morrison & Foerster LLP

[57] **ABSTRACT**

The invention provides new methods for the treatment of diabetes mellitus, including type I, type II, and insulin resistant diabetes (both type I and type II). The methods of the invention employ administration of rhIGF-I/IGFBP-3 complex to a subject suffering from the symptoms of diabetes mellitus. Administration of rhIGF-I/IGFBP-3 to a subject suffering from the symptoms of diabetes mellitus results in amelioration or stabilization of the symptoms of diabetes.

14 Claims, No Drawings